诺华去铁药地拉罗司售价多少？

It was developed by Novartis and was the first oral iron chelator approved by the FDA for routine use in 2005. The FDA granted deferasirox orphan drug status for the treatment of iron overload in non-transfusion-dependent thalassemia. It is currently on the market in more than 80 countries.

The oral suspension and dispersible tablets marketed in the United States are approved for the treatment of chronic iron overload due to transfusion in adult and pediatric patients 2 years and older and chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome.

In 2012, deferasirox was approved in the EU for the treatment of chronic iron overload thalassemia in patients aged 6 years and older due to frequent blood transfusions (hematocrit ≥7ml/kg/month). It is also approved for the treatment of chronic iron overload caused by blood transfusions when deferoxamine treatment is contraindicated or insufficient.

In Japan, Novartis deferasirox is approved for the treatment of transfusion-induced iron overload.

Novartis focuses on the growth areas of pharmaceuticals and healthcare, with a diversified business portfolio of innovative medicines, preventive vaccines and diagnostics, as well as consumer healthcare products to best meet the needs of patients and society. Novartis is the only company that leads in all four of the above areas.

How much does Novartis’ iron-removing drug deferasirox cost?

According to Medical Companion Travel, the price of Novartis abroad is relatively close to the people. The specification is 400mg*30 tablets/box and the price is around 400$. Due to the floating exchange rate, the price is different. Please consult Medical Companion Travel for the specific price!

Recommended related hot articles: /newsDetail/97212.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.